Champions Oncolo Stock Price, News & Analysis

Champions Oncology (NASDAQ:CSBR) has announced that seventeen abstracts have been accepted for presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, scheduled for April 25-30, 2025.

The presentations will showcase the company's research in multiple areas, including:

• Innovative in vivo and organoid platforms for oncology and immuno-oncology drug testing
• AI-driven models using multi-omics datasets for patient outcome prediction

CEO Ronnie Morris highlighted that these presentations demonstrate how Champions' proprietary PDX bank and multi-omics dataset are advancing oncology research and supporting biopharma partners in accelerating drug development.

Champions Oncology (NASDAQ:CSBR) has announced significant enhancements to its bioanalytical services portfolio. The company has integrated multiple global Cytek Aurora flow cytometers to expand its capabilities and appointed Troy Tremaine, MBA, to lead Bioanalytical Commercial Strategy.

The addition of Cytek Aurora instruments strengthens Champions' existing spectral and conventional flow cytometry capabilities, enabling higher complexity spectral analysis. Troy Tremaine brings decades of commercial leadership experience in the preclinical and bioanalytical space across multiple therapeutic areas.

CEO Ronnie Morris expressed enthusiasm about these investments, highlighting how the Cytek Aurora instruments will enhance their competitiveness in this expanding market.

Champions Oncology (NASDAQ:CSBR) reported strong Q2 fiscal 2025 results with revenue increasing 17% to $13.5 million and adjusted EBITDA of $1.1 million. The company achieved net income of $730,000 and maintained a gross profit margin of 45%. First half 2025 performance showed 14% revenue growth to $27.6 million with net income of $2.1 million.

Total costs decreased by $771,000 (5.7%) compared to Q2 fiscal 2024. The company implemented operational improvements and efficiencies, leading to increased revenue conversion. Management projects annual revenue growth of 10-15%, supported by core business strength and new data platform revenue contributions. The company ended the quarter with $2.8 million cash and no debt.

Champions Oncology (NASDAQ:CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has scheduled its second quarter financial results announcement for Wednesday, December 11, 2024, after market close. The company will host a conference call at 4:30 P.M. EST to discuss the results for the quarter ended October 31, 2024. Investors can join via phone or access the replay through the company's website within 72 hours.

Champions Oncology (Nasdaq: CSBR) has announced a licensing agreement with Weill Cornell Medicine through the Center for Technology Licensing. This collaboration grants Champions Oncology exclusive rights to distribute and commercialize Weill Cornell Medicine's hematological patient-derived xenograft (PDX) models.

The PDX models were developed by Dr. Giorgio Inghirami, Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine. Champions Oncology will serve as a repository to distribute these models to academic institutions worldwide, enhancing its position in the heme-oncology field.

This strategic partnership aligns with Champions Oncology's commitment to providing advanced preclinical oncology solutions and strengthens its portfolio in hematological research. The collaboration is expected to facilitate rapid and scalable access to these unique PDXs for both biopharma partners and academic institutions.

Champions Oncology (NASDAQ:CSBR) reported strong financial results for Q1 FY2025. Revenue increased 12% to $14.1 million, with improved margin of 50%. The company achieved adjusted EBITDA of $2.0 million and net income of $1.3 million. Cost reductions and operational efficiencies contributed to profitability. Total costs decreased by $2.4 million (15.8%) compared to Q1 FY2024. The company ended the quarter with $2.9 million in cash and no debt. CEO Ronnie Morris expressed cautious optimism about weathering the business downturn and positioning for future growth.

Champions Oncology (CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has announced it will release its financial and operational results for the first quarter ended July 31, 2024, on Wednesday, September 11, 2024, after market close. The company will host a conference call to discuss the results at 4:30 P.M. EDT on the same day. Investors can join the call using the provided domestic and international dial-in numbers and access code. A replay of the call will be available via phone or through the company's website within 72 hours of the call.

Champions Oncology (Nasdaq: CSBR) reported its financial results for Q4 and fiscal year 2024. Q4 revenue increased 7% to $14 million, with an adjusted EBITDA income of $884,000. However, annual revenue decreased 7% to $50.2 million, with a fiscal year 2024 adjusted EBITDA loss of $3.9 million. The company faced challenges due to the biotech sector's funding environment and pharmaceutical spending patterns. Cost-cutting measures and operational efficiencies were implemented, showing positive results in Q4. Champions is optimistic about returning to consistent profitability in fiscal 2025. The company ended Q4 with a cash position of $2.6 million and no debt.

Champions Oncology (NASDAQ: CSBR), a global provider of preclinical and clinical research services, will announce its financial and operational results for Q4 and the fiscal year ended April 30, 2024, on July 18, 2024, after market close.

The company will hold a conference call at 4:30 P.M. EST (1:30 P.M. PST) to discuss the results. Participants can join the call domestically by dialing 888-506-0062 or internationally at 973-528-0011 using access code 135832. A replay will be available within 72 hours by dialing 877-481-4010 (Domestic) or 919-882-2331 (International), passcode: 50895, or through the investor section of the company's website.